Q-omics provides the consensus-scored UHRF1BP1L profile across patient tissues and cancer cell-line models. UHRF1BP1L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UHRF1BP1L is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, UHRF1BP1L protein abundance shows 22,302 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where UHRF1BP1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UHRF1BP1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UHRF1BP1L survival associations across molecular data types. UHRF1BP1L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UHRF1BP1L RNA expression–survival associations across cancer types. High UHRF1BP1L expression shows unfavorable associations in BLCA, UVM and LUSC, but favorable associations in KIRC, SKCM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UHRF1BP1L RNA expression.
This table summarizes UHRF1BP1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for UHRF1BP1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UHRF1BP1L shows lower tumor expression in COAD, THCA and LUSC and higher tumor expression in HNSC, BRCA and KIRC. The COAD box plot shows higher UHRF1BP1L RNA expression in normal versus tumor tissue (log2 FC = −0.533, t-test p < 0.001).
This table shows molecular features associated with UHRF1BP1L in patient tissues and cancer cell lines. In patient samples, UHRF1BP1L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, UHRF1BP1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
